Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kiniksa Pharmaceuticals Ltd
KNSA | US
42.45
USD-0.01
-0.02%
KNSA | US
About Kiniksa Pharmaceuticals Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/04/2026
Close
42.45
Open
42.16
High
43.46
Low
41.49
Kiniksa Pharmaceuticals Ltd. a biopharmaceutical company focuses on discovering acquiring developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST an interleukin-1alpha and interleukin-1beta for the treatment of recurrent pericarditis which is an inflammatory cardiovascular disease; Mavrilimumab a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab a monoclonal antibody that completed Phase 2b clinical trial for the treatment of prurigo nodularis a chronic inflammatory skin condition; and KPL-404 a monoclonal antibody inhibitor of the CD40- CD154 interaction a T-cell co-stimulatory signal critical for B-cell maturation immunoglobulin class switching and type 1 immune response. Kiniksa Pharmaceuticals Ltd. was incorporated in 2015 and is based in Hamilton Bermuda.
View LessKNSA | US
Risk
36.2
Sharpe
2.48
Luna's Score
61/100
Recommendation
Hold
Luna says (KNSA | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Midcap (2B - 10B USD)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
29.3%1 month
36.2%3 months
37.4%6 months
35.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.30
Debt to equity
0.03
Debt to assets
0.02
Ent. to EBITDA
-44.93
Ent. to rev.
4.91
PEG
-
Other Fundamentals
EBITDA
-25.47M
MarketCap
3.02B
MarketCap(USD)
3.02B
Div. yield
-
Op. margin
-0.11
Erngs. growth
550.00
Rev. growth
52.00
Ret. on equity
-2.42
Short ratio
8.51
Short perc.
13.04
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
8.52
Range1M
8.54
Range3M
11.63
Volumes: Market Activity
Rel. volume
1.72
Price X volume
45.61M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -44.93 | - | Cheaper |
| Ent. to Revenue | 4.91 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.30 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 37.40 | - | Lower Risk |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 3.02B | - | Par |
